1. Home
  2. Shareholder and Investor Information
  3. Understanding RaQualia Pharma! RaQualia FAQ
  4. RaQualia’s History

Shareholder and Investor Information

RaQualia’s History

fig. RaQualia's History

RaQualia was launched from Pfizer Inc.'s Research Laboratories in Japan. This research facility served as one of Pfizer's discovery research bases and conducted drug discovery research primarily in pain and gastrointestinal disease. In January 2007, Pfizer decided to close the facility as part of a global restructuring of its R&D and business operations.

Then-Director Dr. Atsushi Nagahisa and over 70 staff from the Laboratories decided to form an R&D-oriented drug discovery company from the primary functions of the facility.

The company was founded in February 2008. In July 2008, RaQualia assumed the former Central Laboratories' human resources, physical assets, and R&D portfolio, and began business.

In July 2011, RaQualia listed on the Osaka Securities Exchange's JASDAQ Growth Market.

  • Previous
  • Next
  • FAQ

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics